What the 12-Digit NDC Means for Government Pricing, Rebates, and Reporting

The FDA recently finalized a rule transitioning National Drug Codes (NDCs) from the current 10 and 11 digit formats to a standardized 12-digit NDC structure (6-4-2). Implementation begins March 7, 2033, with a three-year transition period through March 2036. While the timeline provides ample runway, pharmaceutical manufacturers should begin evaluating potential system, data, and reporting impacts now.

Why the FDA is Moving to a 12-Digit NDC Format

The current NDC format exists in several configurations, usually in 10- and 11-digit formats (e.g., 5-4-2, 5-3-2, 5-4-1). These variations often require the use of leading zeros, creating inconsistencies across healthcare, regulatory, and supply chain systems.

The FDA’s finalized rule introduces a uniform 12-digit format (6-4-2):

• 6 digits – Labeler code
• 4 digits – Product code
• 2 digits – Package code

This structure is intended to improve data consistency, scalability, and interoperability across regulatory reporting, healthcare systems, and pharmaceutical supply chains, as well as providing additional NDC codes for a growing number of products databased.

Timeline for Implementation

Operational Considerations for Manufacturers

Although the implementation timeline is nearly a decade away, the NDC is deeply embedded across pharmaceutical operations. Organizations should eventually evaluate impacts in areas such as:

• Government Pricing calculations
• Rebate processing and chargebacks
• State Price Transparency reporting
• Data warehouses and analytics platforms
• EDI transactions and supply chain integrations
• ERP and regulatory reporting systems

Early awareness allows organizations to incorporate NDC format changes into long-term technology roadmaps and system modernization initiatives.

How Prescription Analytics is Monitoring the Change

Prescription Analytics is closely monitoring the FDA’s finalized rule and coordinating with our technology teams and partners across the pharmaceutical supply chain to anticipate potential data and system impacts.

Because the NDC is embedded across pharmaceutical data and reporting workflows, we continue to track regulatory developments that may affect how manufacturers manage and report drug data.

As additional guidance and industry best practices emerge, we will continue sharing updates and insights with our clients and partners.